全文获取类型
收费全文 | 1955篇 |
免费 | 153篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 67篇 |
妇产科学 | 12篇 |
基础医学 | 239篇 |
口腔科学 | 33篇 |
临床医学 | 286篇 |
内科学 | 353篇 |
皮肤病学 | 35篇 |
神经病学 | 193篇 |
特种医学 | 355篇 |
外科学 | 196篇 |
综合类 | 43篇 |
一般理论 | 3篇 |
预防医学 | 94篇 |
眼科学 | 13篇 |
药学 | 109篇 |
中国医学 | 6篇 |
肿瘤学 | 78篇 |
出版年
2023年 | 10篇 |
2022年 | 12篇 |
2021年 | 28篇 |
2020年 | 17篇 |
2019年 | 25篇 |
2018年 | 45篇 |
2017年 | 30篇 |
2016年 | 32篇 |
2015年 | 44篇 |
2014年 | 54篇 |
2013年 | 78篇 |
2012年 | 67篇 |
2011年 | 87篇 |
2010年 | 73篇 |
2009年 | 97篇 |
2008年 | 91篇 |
2007年 | 76篇 |
2006年 | 61篇 |
2005年 | 52篇 |
2004年 | 54篇 |
2003年 | 45篇 |
2002年 | 63篇 |
2001年 | 42篇 |
2000年 | 50篇 |
1999年 | 47篇 |
1998年 | 57篇 |
1997年 | 61篇 |
1996年 | 76篇 |
1995年 | 61篇 |
1994年 | 52篇 |
1993年 | 59篇 |
1992年 | 31篇 |
1991年 | 15篇 |
1990年 | 30篇 |
1989年 | 50篇 |
1988年 | 42篇 |
1987年 | 46篇 |
1986年 | 43篇 |
1985年 | 34篇 |
1984年 | 29篇 |
1983年 | 17篇 |
1982年 | 27篇 |
1981年 | 18篇 |
1980年 | 12篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1977年 | 12篇 |
1976年 | 14篇 |
1975年 | 13篇 |
1967年 | 4篇 |
排序方式: 共有2119条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Mathieu Beaulieu David Williamson Gilbert Pichette Jean Lachaine 《Infection control and hospital epidemiology》2007,28(11):1305-1307
Our study was conducted to determine whether use of gastric acid-suppressive agents increased the risk of Clostridium difficile-associated disease (CDAD) in a medical intensive care unit of one of the first hospitals to be threatened by the current CDAD epidemic in Quebec, Canada. Our findings suggest that efforts to determine risk factors for CDAD should focus on other areas, such as older age and antibiotic use. 相似文献
3.
4.
5.
6.
7.
8.
Pierre Beaulieu 《Journal canadien d'anesthésie》2006,53(8):769-775
PURPOSE: Cannabinoids have been shown to have analgesic properties in animal studies, but a potential role for these drugs in acute pain management has not been established. It was hypothesized that nabilone, an oral cannabinoid synthetic tetrahydrocannabinol analogue, decreases morphine consumption, pain scores, nausea and vomiting following major surgery. METHODS: A double-blind, randomized, placebo-controlled, parallel-group pilot trial compared the effects of two different doses, 1 mg (n = 11) and 2 mg (n = 9) of nabilone, ketoprofen 50 mg (n = 11) or placebo (n = 10), given at eight-hour intervals for 24 hr. Outcomes included morphine consumption, pain scores and emesis after major surgery. Secondary outcomes included patient tolerability of the study medication. RESULTS: Forty-one patients (mean age 52 +/- 2 yr) undergoing gynecologic (46%), orthopedic (44%), or other (10%) surgery were recruited. Cumulative 24-hr morphine consumption was not different between the four groups, but pain scores at rest and on movement were significantly higher in the 2 mg nabilone group compared to the other groups. There were no significant differences between groups with respect to episodes of nausea and vomiting, quality of sleep, sedation, euphoria, pruritus, or the number and severity of adverse events. No serious adverse event was recorded. CONCLUSIONS: Contrary to the main hypothesis, high dose nabilone in the presence of morphine patient controlled analgesia is associated with an increase in pain scores in patients undergoing major surgery. 相似文献
9.
10.